Summary
The provided statements do not address ENTRESTO fetal toxicity/pregnancy guidance from the label text. No alignment can be assessed against the supplied FDA label sections (5.1 and 8.1) for fetal harm.
Category Scores
Accurate Statements
Unsupported Statements
There is no single life expectancy number for Entresto (sacubitril/valsartan).
Irrelevant to the provided FDA label sections (5.1/8.1) for fetal toxicity; not supported or contradicted by the supplied label excerpts.
Survival on Entresto depends mostly on the underlying heart condition.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified against provided label text.
Survival on Entresto depends on age.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Survival on Entresto depends on kidney function.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Survival on Entresto depends on blood pressure.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Survival on Entresto depends on other illnesses.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Survival on Entresto depends on how well the condition is controlled.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto reduces the risk of death compared with older standard care for people with chronic heart failure.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
In clinical trials, Entresto lowered the risk of death compared with enalapril.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
In clinical trials, Entresto reduced heart-failure hospitalizations compared with enalapril.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Trials measure risk reduction, not a guarantee of a specific lifespan.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto works by improving how the body handles stress signals and fluid balance.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto can help the heart fail more slowly.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto tends to result in fewer heart-failure events that drive emergency care and hospital stays.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto tends to lower the risk of progressive worsening.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto provides better long-term outcomes than older therapies in studied groups.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto is used for certain types of heart failure, commonly reduced ejection fraction.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto is used for some cases in other approved heart-failure categories depending on eligibility.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
People with very low blood pressure may need dose adjustments when using Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
People with significant kidney impairment may need dose adjustments when using Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
People with certain medication intolerances may not be good candidates for Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Low blood pressure is a main safety/tolerability issue with Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Low blood pressure with Entresto can cause dizziness and fainting.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Worsening kidney function can occur in some patients taking Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Elevated potassium (hyperkalemia) can occur with Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections as a general adverse reaction; cannot be verified.
Angioedema is a rare but serious risk with Entresto.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
The angioedema risk with Entresto is especially relevant if there is a history of angioedema.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Stopping or reducing Entresto because of side effects can change how well heart failure is controlled.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Some people live many years on Entresto when the heart failure is diagnosed early.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Some people live many years on Entresto when doses are optimized.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Some people live many years on Entresto when blood pressure and kidney function stay stable.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Some people live many years on Entresto when they follow other therapies when indicated (including beta blockers and mineralocorticoid receptor antagonists).
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Some people live many years on Entresto when they avoid triggers that worsen heart failure.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
For others with advanced disease, Entresto may extend life and reduce hospitalizations without making life expectancy normal.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto may extend life in advanced disease.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto may reduce hospitalizations in advanced disease.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Entresto may reduce hospitalizations without making life expectancy normal in advanced disease.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
A cardiologist can estimate a more personalized outlook based on current functional status and test results.
Not addressed in the supplied fetal toxicity/pregnancy label sections; cannot be verified.
Contradictions
Important Omissions
Statement that ENTRESTO can cause fetal harm when administered to a pregnant woman and guidance to consider alternative therapy and discontinue ENTRESTO when pregnancy is detected (5.1; 8.1 Risk Summary).
Importance:
High
Description of fetal/neonatal adverse reactions associated with exposure during the 2nd and 3rd trimesters (e.g., reduced fetal renal function/oligohydramnios-related outcomes, fetal lung hypoplasia, skeletal deformations, hypotension, death) and neonatal monitoring/management (8.1 Clinical Considerations).
Importance:
High
Guidance that if there is no appropriate alternative and if the drug is considered lifesaving for the mother, advise the pregnant woman of potential fetal risk (5.1; 8.1 Risk Summary).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The label excerpt emphasizes fetal toxicity and specific discontinuation/alternative-consideration guidance upon pregnancy detection. The provided statements omit these pregnancy-related safety warnings, which could lead to omission of critical risk counseling and discontinuation guidance when pregnancy occurs.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Primary Issue
The response does not include or reflect the FDA label’s pregnancy/fetal toxicity warnings and management instructions (Sections 5.1 and 8.1).
Suggested Improvement
Include that ENTRESTO can cause fetal harm; recommend considering alternative therapy and discontinuing ENTRESTO when pregnancy is detected; describe key fetal/neonatal outcomes associated with second/third trimester exposure and the need for fetal ultrasound assessment and neonatal monitoring/support after in utero exposure.